Advertisement

BioDrugs

, Volume 14, Issue 4, pp 211–220 | Cite as

A Guide to the Use of Interferon-Alpha in the Management of Chronic Myelogenous Leukaemia

  • Jorge Cortes
  • Susan O’Brien
Disease Management

Abstract

Interferon-alpha (IFNα) can induce major cytogenetic responses in 30 to 40% of patients with chronic myelogenous leukaemia (CML) and up to 50% when combined with cytarabine (ara-C). These responses translate into a survival advantage. However, the management of patients treated with IFNα requires experience to optimise the therapy. The optimal dose should be used and the addition of ara-C should be considered. It is advisable to lower the white blood cell count (WBC) before the start of therapy and increase the dose to the ideal dose gradually over 1 to 2 weeks. Some myelosuppression should be tolerated to keep a WBC in the range of 2 to 4 × 109/L. Dosages should be adjusted as needed when grade 3 or persistent grade 2 toxicity occurs, and adverse effects should be managed promptly and aggressively to improve tolerance. Patients should be monitored closely with cytogenetic and possibly other analyses such as fluorescent in situ hybridisation (FISH) and polymerase chain reaction (PCR) to determine response. The duration of therapy is controversial, but it should be kept in mind that whenever the decision is made to use IFNα for therapy in CML, the patient should be given the best opportunity to achieve a cytogenetic response as this will probably translate into a survival advantage.

Keywords

Cytarabine Chronic Myelogenous Leukaemia Hydroxyurea Busulfan Cytogenetic Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691–703PubMedGoogle Scholar
  2. 2.
    Kantarjian HM, Smith T, O’Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon — therapy. Ann Intern Med 1995; 122: 254–61PubMedGoogle Scholar
  3. 3.
    The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994; 330: 820–5CrossRefGoogle Scholar
  4. 4.
    Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392–7PubMedCrossRefGoogle Scholar
  5. 5.
    Alimena G, Morra E, Lazzarino M, et al. Interferon alpha-2b as therapy for Ph’-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1998; 72: 642–7Google Scholar
  6. 6.
    Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064–77PubMedGoogle Scholar
  7. 7.
    Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906–16PubMedGoogle Scholar
  8. 8.
    Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975–84PubMedGoogle Scholar
  9. 9.
    Hehlmann R, Hochhaus A, Kolb HJ, et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–77PubMedGoogle Scholar
  10. 10.
    Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394–401PubMedGoogle Scholar
  11. 11.
    Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronicphase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981–90PubMedGoogle Scholar
  12. 12.
    Giralt SA, Kantarjian HM, Talpaz M, et al. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1993; 11: 1055–61PubMedGoogle Scholar
  13. 13.
    Freund M, von Wussow P, Diedrich H, et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 1989; 72: 350–6PubMedCrossRefGoogle Scholar
  14. 14.
    Anger B, Porzsolt F, Leichtle R, et al. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 1989; 58: 275–8PubMedCrossRefGoogle Scholar
  15. 15.
    Schofield JR, Robinson WA, Murphy JR, et al. Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia [see comments]. Ann Intern Med 1994; 121: 736–44PubMedGoogle Scholar
  16. 16.
    Montastruc M, Mahon FX, Faberes C, et al. Response to recombinant interferon alpha in patients with chronic myelogenous leukemia in a single center: results and analysis of predictive factors. Leukemia 1995; 9: 1997–2002PubMedGoogle Scholar
  17. 17.
    Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group [see comments]. N Engl J Med 1997; 337: 223–9PubMedCrossRefGoogle Scholar
  18. 18.
    Kantarjian HM, O’Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999; 17: 284–92PubMedGoogle Scholar
  19. 19.
    O’Brien S, Kantarjian H, Koller C, et al. Sequential homo-harringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999; 93: 4149–53PubMedGoogle Scholar
  20. 20.
    Stenke L, Samuelsson J, Palmblad J, et al. Elevated white blood cell synthesis of leukotriene C4 in chronic myelogenous leukaemia but not in polycythaemia vera. Br J Haematol 1990; 74: 257–63PubMedCrossRefGoogle Scholar
  21. 21.
    Talpaz M, Kantarjian H, Kurzrock R, et al. Interferon-alpha 0produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532–8Google Scholar
  22. 22.
    Sacchi S, Kantarjian H, O’Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401–7PubMedGoogle Scholar
  23. 23.
    Cortes J, Kantarjian H, O’Brien S, et al. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996; 100: 452–5PubMedCrossRefGoogle Scholar
  24. 24.
    Guo JQ, Lian JY, Xian YM, et al. BCR-ABLprotein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 1994; 83: 3629–37PubMedGoogle Scholar
  25. 25.
    Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587–99PubMedCrossRefGoogle Scholar
  26. 26.
    Le Gouill S, Talmant P, Milpied N, et al. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 2000; 18: 1533–8PubMedGoogle Scholar
  27. 27.
    Hochhaus A, Lin F, Reiter A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996 87: 1549–55PubMedGoogle Scholar
  28. 28.
    Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62–6PubMedGoogle Scholar
  29. 29.
    Wilhelm M, Ramos CM, O’Brien S. Effect of interferon-alpha (IFN-A) therapy on bone marrow (BM) fibrosis in chronic myelogenous leukemia (CML) [abstract #3537]. Blood 1996; 88 Suppl 1: 10Google Scholar
  30. 30.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study. Br J Haematol 2000; 108: 64–71PubMedCrossRefGoogle Scholar
  31. 31.
    Bhatia R, Wayner EA, McGlave PB, et al. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia he-matopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function [see comments]. J Clin Invest 1994; 94: 384–91PubMedCrossRefGoogle Scholar
  32. 32.
    Upadhyaya G, Guba SC, Sih SA, et al. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 1991; 88: 2131–6PubMedCrossRefGoogle Scholar
  33. 33.
    Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118–22PubMedGoogle Scholar
  34. 34.
    Talpaz M, Estrov Z, Kantarjian H, et al. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994; 94: 1383–9PubMedCrossRefGoogle Scholar
  35. 35.
    Seong DC, Kantarjian HM, Ro JY, et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995; 86: 2343–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Jorge Cortes
    • 1
  • Susan O’Brien
    • 1
  1. 1.Department of LeukaemiaThe University of Texas, M.D. Anderson Cancer CenterTexasUSA

Personalised recommendations